arbutus biopharma corporation (nasdaq:abus) is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis b infection, a disease of the liver caused by hepatitis b virus (hbv). we are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the hbv treatment landscape and cure hepatitis b virus disease. in addition to our hbv assets, we are developing a pipeline of programs that leverage our expertise in rna interference (rnai) therapeutics and our lipid nanoparticle (lnp) technology.
Company profile
Ticker
ABUS
Exchange
Website
CEO
William Collier
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
TEKMIRA PHARMACEUTICALS CORP, TEKMIRA PHARMACEUTICALS Corp
SEC CIK
Corporate docs
Subsidiaries
Arbutus Biopharma Inc. ...
ABUS stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
10 Apr 24
DEF 14A
Definitive proxy
10 Apr 24
8-K
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
4 Apr 24
10-K
2023 FY
Annual report
5 Mar 24
8-K
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
29 Feb 24
8-K
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
8 Jan 24
8-K
Departure of Directors or Certain Officers
4 Jan 24
8-K
Preliminary data in subset of patients given imdusiran and then VTP-300 show early signs of immune activation
9 Nov 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update
7 Nov 23
Transcripts
ABUS
Earnings call transcript
2023 Q4
29 Feb 24
ABUS
Earnings call transcript
2023 Q3
7 Nov 23
ABUS
Earnings call transcript
2023 Q2
3 Aug 23
ABUS
Earnings call transcript
2023 Q1
4 May 23
ABUS
Earnings call transcript
2022 Q4
2 Mar 23
ABUS
Earnings call transcript
2022 Q3
9 Nov 22
ABUS
Earnings call transcript
2022 Q3
9 Nov 22
ABUS
Earnings call transcript
2022 Q2
4 Aug 22
ABUS
Earnings call transcript
2022 Q1
5 May 22
ABUS
Earnings call transcript
2021 Q4
3 Mar 22
Latest ownership filings
SC 13G/A
Whitefort Capital Management, LP
14 Feb 24
SC 13G/A
Two Seas Capital LP
14 Feb 24
SC 13G/A
BlackRock Inc.
12 Feb 24
4
J. Christopher Naftzger
5 Feb 24
4
Karen Sims
5 Feb 24
4
DAVID C HASTINGS
5 Feb 24
4
Michael J. Sofia
5 Feb 24
4
Michael J. McElhaugh
5 Feb 24
SC 13G
Two Seas Capital LP
21 Nov 23
SC 13G
Whitefort Capital Management, LP
11 Sep 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 17.53 mm | 17.53 mm | 17.53 mm | 17.53 mm | 17.53 mm | 17.53 mm |
Cash burn (monthly) | 3.22 mm | 539.42 k | 7.19 mm | 6.66 mm | 7.26 mm | 7.14 mm |
Cash used (since last report) | 22.18 mm | 3.71 mm | 49.48 mm | 45.86 mm | 50.00 mm | 49.14 mm |
Cash remaining | -4.65 mm | 13.82 mm | -31.95 mm | -28.33 mm | -32.47 mm | -31.60 mm |
Runway (months of cash) | -1.4 | 25.6 | -4.4 | -4.3 | -4.5 | -4.4 |
Institutional ownership, Q3 2023
61.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 96 |
Opened positions | 5 |
Closed positions | 18 |
Increased positions | 35 |
Reduced positions | 23 |
13F shares | Current |
---|---|
Total value | 143.28 bn |
Total shares | 109.62 mm |
Total puts | 514.20 k |
Total calls | 573.10 k |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
ROIV Roivant Sciences | 38.85 mm | $160.83 mm |
Whitefort Capital Management | 11.90 mm | $24.15 bn |
BLK Blackrock | 10.27 mm | $20.86 bn |
Kairos Capital Management | 8.28 mm | $16.81 bn |
Vanguard | 5.95 mm | $12.07 bn |
MS Morgan Stanley | 5.26 mm | $10.68 bn |
Woodline Partners | 4.72 mm | $9.58 bn |
Hudson Bay Capital Management | 4.15 mm | $8.42 bn |
Geode Capital Management | 2.70 mm | $5.48 bn |
STT State Street | 2.16 mm | $4.39 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Feb 24 | Michael J. Sofia | Common Shares | Sell | Dispose S | No | Yes | 2.3125 | 9,982 | 23.08 k | 1,485,121 |
2 Feb 24 | McElhaugh Michael J. | Common Shares | Sell | Dispose S | No | Yes | 2.3125 | 10,164 | 23.50 k | 1,504,793 |
2 Feb 24 | Karen Sims | Common Shares | Sell | Dispose S | No | Yes | 2.3125 | 4,358 | 10.08 k | 125,542 |
2 Feb 24 | Hastings David C | Common Shares | Sell | Dispose S | No | Yes | 2.3125 | 9,593 | 22.18 k | 181,907 |
1 Feb 24 | Michael J. Sofia | Common Shares | Grant | Acquire A | No | No | 0 | 109,500 | 0.00 | 1,495,103 |
1 Feb 24 | Michael J. Sofia | Stock Option Common Shares | Grant | Acquire A | No | No | 2.4 | 437,800 | 1.05 mm | 437,800 |
1 Feb 24 | McElhaugh Michael J. | Common Shares | Grant | Acquire A | No | No | 0 | 123,800 | 0.00 | 1,514,957 |
1 Feb 24 | McElhaugh Michael J. | Stock Option Common Shares | Grant | Acquire A | No | No | 2.4 | 495,100 | 1.19 mm | 495,100 |
1 Feb 24 | J. Christopher Naftzger | Common Shares | Grant | Acquire A | No | No | 0 | 95,100 | 0.00 | 95,100 |
1 Feb 24 | J. Christopher Naftzger | Stock Option Common Shares | Grant | Acquire A | No | No | 2.4 | 380,500 | 913.20 k | 380,500 |
News
Arbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From Judge
4 Apr 24
Moderna Shares Slip Over Covid Vaccine Patent Dispute, But Chart Signals Potential Rebound Ahead
4 Apr 24
JMP Securities Reiterates Market Outperform on Arbutus Biopharma, Maintains $4 Price Target
4 Apr 24
Arbutus Biopharma Announces Claim Construction Ruling In Ongoing Patent Infringement Lawsuit Against Moderna
4 Apr 24
Arbutus Stock Soars 20% As It Heads To Trial With Moderna In Covid Vaccine Patent Claim
3 Apr 24
Press releases
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
18 Apr 24
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
4 Apr 24
Arbutus to Participate in Two Upcoming Investor Conferences
8 Mar 24
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
29 Feb 24
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
15 Feb 24